Sunesis Pharmaceuticals Receives Milestone Payment From Biogen Idec
Published In: Business, California 
Monday, July 13, 2009 8:00 AM
< Archive for Jan 2012 >
SuMoTuWeThFrSa
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
SOUTH SAN FRANCISCO, Calif., July 13 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers, today announced that it has received a $1.5 million milestone payment from Biogen Idec (Nasdaq: BIIB) for the selection of a Raf kinase inhibitor development candidate for the treatment of cancer. Biogen Idec is currently conducting IND-enabling GLP preclinical work with the Raf kinase development candidate.

"While our internal efforts are focused on the successful development of voreloxin, we are extremely pleased by the continued progress being made by Biogen Idec to advance a Raf kinase inhibitor toward the clinic," said Daniel Swisher, Sunesis' Chief Executive Officer.

In August 2004 the companies entered into a collaboration to discover and develop small molecule cancer therapeutics targeting kinases, a family of cell signaling enzymes that play a major role in the progression of cancer. The research term of this collaboration ended in June of 2008. Sunesis retains an option to participate in the co-development and co-promotion of the Raf kinase inhibitor resulting from this collaboration.

About Sunesis Pharmaceuticals
Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. Sunesis has built a highly experienced cancer drug development organization committed to advancing voreloxin in multiple indications to improve the lives of people with cancer. For additional information on Sunesis Pharmaceuticals, please visit http://www.sunesis.com.

SUNESIS and the logo are trademarks of Sunesis Pharmaceuticals, Inc.


Investor Contact: Media Contact:
Sunesis Pharmaceuticals, Inc. Sunesis Pharmaceuticals, Inc.
Eric Bjerkholt Dan Weinseimer
650-266-3717 650-266-3739



SOURCE Sunesis Pharmaceuticals, Inc.


 
Monday, July 13, 2009 8:00 AM

Share Socially:
BlinkListBlinkList del.icio.usdel.icio.us DiggDigg FurlFurl ma.gnoliama.gnolia redditreddit SimpySimpy SpurlSpurl BlogMarksBlogMarks NewsvineNewsvine Share on Facebook Sphere: Related Content

Related Press Releases

Reportlinker Adds Biogen Idec Inc.: PharmaVitae Profile
Published In: Business, New York 
Thursday, April 1, 2010 1:30 PM
ISS Supports Icahn Nominees for Biogen Idec Board
Published In: Business, New York 
Thursday, May 28, 2009 12:13 PM
Corey McPherson Nash Partners with Biogen Idec
Published In: Business, Massachusetts 
Thursday, February 11, 2010 3:08 PM
Sunesis Pharmaceuticals Receives NASDAQ Notification
Published In: Business, California 
Friday, September 18, 2009 4:30 PM
Trillium and Biogen Idec enter into global license agreement
Published In: Business, Ontario 
Tuesday, January 12, 2010 10:00 AM
Contact Us | Terms of Use | Trademarks | Privacy Statement
(c) 2008-2009 Press Related